United States
United States

Time filter

Source Type

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. The personalized medicine (global & USA) market is presented as follows: By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) By Therapy (Cancer, Cardiovascular, Infectious Disease) Key Opinion Leaders that contributed to interview questions within the report include: - Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group - Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland - Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC - Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland - Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine - Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine - David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine - Deborah Phippard, PhD, Vice President, Research, Precision for Medicine - Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine A wealth of financial data & business strategy information is provided including: - Company financials, sales & revenue figures - Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies - Business Model Strategies for Providers. Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) - Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: - Key strengths, weaknesses and threats influencing leading player position within the market - Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) - Top fastest growing market segments and emerging opportunities - Top pharmaceutical companies within the IPM by market share and revenue - Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos - Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) - CE-marked Personalized Medicine/Diagnostic Tests - FDA Advances in Personalized Medicine Regulation What you will gain: - An in-depth understanding of the global personalized medicine market and it's environment - Current market facts, figures and product lines of key players in the industry - Emerging trends in key markets such as the US, UK, Germany and France - Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing - Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies - FDA approved pharmacogenetic tests and recognized biomarkers - Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry This report tackles key concerns to the personalized medicine market such as: - Lack of regulatory policy and legislation in the US and Europe - Reimbursement schemes and payers concerns - Transition of investigational diagnostic assays and therapeutics to clinical practice - Direct to consumer (DTC) test kits and implications for the public This report will tell you if the companies mentioned are: - Strong, competitive players - Pooling their resources for specific growth and therapeutic areas - Investing strategically in R&D - Have a history of strategic M&A activity Key Topics Covered: 1.0 Executive Summary 2.0 Introduction and Background 3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics 4.0 Personalized Medicine and Integration into the Healthcare System 5.0 Private and Public Funding and Personalized Medicine Reimbursement 6.0 European Personalized Medicine Market - Payments and Investment 7.0 Personalized Medicine -Business Model Analysis 8.0 Personalized Medicine Main Industry Players 9.0 Personalized Medicine Market Analysis 10.0 Strengths and Advantages of Personalized Medicine 11.0 Restraints of the Personalized Medicine Market 12.0 Personalized Medicine and Regulatory Policies 13.0 Final Summary and Future Perspectives 14.0 Interviews with Key Opinion Leaders Companies Mentioned For more information about this report visit http://www.researchandmarkets.com/research/wk98zk/personalized Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-personalized-medicine-targeted-therapeutics-and-companion-diagnostic-market-2017-2021-strategic-analysis-of-industry-trends-technologies-participants-and-environment---research-and-markets-300460730.html


Methods and materials for improving nucleic acid or protein recovery from samples preserved in liquid cytological preservative solutions by utilizing scavenging agents, such as hydrazine- and hydrazide-containing compounds, are provided. Lysis solutions comprising hydrazine- and hydrazide-containing compounds and kits comprising the same are also provided.


Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA:RNA hybrids which can be detected by a variety of methods.


Patent
Qiagen, Inc. | Date: 2012-04-12

The invention relates to a simple, reproducible, fast, and accurate method of quantifying and measuring telomeres in a clinical sample. The invention further relates to kits comprising premixed and optimized buffers, DNA polymerase, primers, and instructions for the detection of telomere length and quantities. Also envisioned are complete kits further including instrumentalities for the detection of telomere length and quantities.


Patent
Qiagen, Inc. | Date: 2012-09-14

The present invention comprises a method that provides fast and reliable results for detecting the presence of a target nucleic acid molecule in a sample.


Methods are provided for genotyping a target nucleic acid in a sample. In various aspects, the methods comprise generating nucleic acid hybrids between probes specific for the genotypes of interest and the target nucleic acid and detecting hybridization in the sample. In other aspects, the methods comprise using multi-probe mixtures to reduce the volume of sample necessary to determine the genotype of the target nucleic acid.


Methods and materials for determining the presence of at least one nucleic acid in a sample are provided, said methods comprising (1) a purification step using sequence specific hybrid capture; (2) an amplification step; and (3) a detection step using two separate sequence-specific polynucleotide probes. Also provided are nucleic acids comprising SEQ ID NO: 1 to SEQ ID NO: 727 and nucleic acid probes and probe sets comprising the same.


A method for isothermal amplification of a target nucleic acid sequence is disclosed. The target nucleic acid is amplified by an enzyme with helicase activity and an enzyme with reverse transcriptase activity and DNA-dependant DNA polymerase activity. Also disclosed is a kit for isothermal amplification of a target nucleic acid sequence, including HPV nucleic acids. The kit comprises a first enzyme with helicase activity and a second enzyme having both reverse transcriptase activity and DNA-dependant DNA polymerase activity.


Patent
Qiagen, Inc. | Date: 2011-01-07

A water treatment apparatus with a first filtration system and a second filtration system is disclosed. The first filtration system provides purified water to an automated assay device. The second filtration system receives wastewater from an outlet and removes contaminants from the wastewater which allows for direct disposal of the wastewater via environmentally responsible means. An automated assay device comprising the water treatment apparatus and a method of treating water used by the automated assay device is also disclosed.


Patent
Qiagen, Inc. | Date: 2012-02-23

Provided are nucleic acids capable of hybridizing to HPV 16 and/or HPV 18 nucleic acids, in particular, mRNA encoding E2 and E6-7 gene products. Such nucleic acids are useful in methods of isolating RNA from a biological sample, methods and means for determining the presence of particular RNA splice-form variants in a biological sample, methods and means for determining the relative ratio of RNA ratios in a biological sample, methods and means for predicting the progression of precancerous cervical lesions, and methods and means for detecting disruption of genes or gene expression.

Loading Qiagen, Inc. collaborators
Loading Qiagen, Inc. collaborators